Xanthomatous Giant Cell Renal Cell Carcinoma
暂无分享,去创建一个
Lisa M Haley | P. Argani | R. Mehra | A. Matoso | Tamara Lotan | C. Chow | J. Ng | Aparna Pallavajjalla | Ming Tseh-Lin | T. Lotan | A. Pallavajjalla
[1] P. Argani,et al. GPNMB expression identifies TSC1/2/mTOR‐associated and MiT family translocation‐driven renal neoplasms , 2022, The Journal of pathology.
[2] P. Argani,et al. Renal cell carcinoma associated with tuberous sclerosis complex (TSC)/mammalian target of rapamycin (MTOR) genetic alterations , 2022, Modern Pathology.
[3] Sourav K. Mishra,et al. Oncocytic renal neoplasms with diffuse keratin 7 immunohistochemistry harbor frequent alterations in the mammalian target of rapamycin pathway , 2021, Modern Pathology.
[4] M. Merad,et al. Histiocytic disorders , 2021, Nature Reviews Disease Primers.
[5] I. Pedrosa,et al. Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney , 2021, Modern Pathology.
[6] M. Sibony,et al. Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1 , 2021, Modern Pathology.
[7] J. Cheville,et al. Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a Single Institutional Experience with Clinicopathological and Molecular Characteristics. , 2021, Human pathology.
[8] T. Guzzo,et al. Acquired Cystic Kidney Disease–associated Renal Cell Carcinoma (ACKD-RCC) Harbor Recurrent Mutations in KMT2C and TSC2 Genes , 2020, The American journal of surgical pathology.
[9] R. Shah,et al. “Renal Cell Carcinoma With Leiomyomatous Stroma” Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity , 2019, The American journal of surgical pathology.
[10] A. Sangoi,et al. Low‐grade oncocytic tumour of kidney (CD117‐negative, cytokeratin 7‐positive): a distinct entity? , 2019, Histopathology.
[11] Lauren L. Ritterhouse,et al. Genetic Underpinnings of Renal Cell Carcinoma With Leiomyomatous Stroma , 2019, The American journal of surgical pathology.
[12] V. Reuter,et al. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm , 2019, The American journal of surgical pathology.
[13] S. Dhanasekaran,et al. Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma. , 2018, European urology.
[14] M. Bonert,et al. “High-grade oncocytic renal tumor”: morphologic, immunohistochemical, and molecular genetic study of 14 cases , 2018, Virchows Archiv.
[15] P. Argani,et al. Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum , 2018, The American journal of surgical pathology.
[16] Lauren L. Ritterhouse,et al. Are Sporadic Eosinophilic Solid and Cystic Renal Cell Carcinomas Characterized by Somatic Tuberous Sclerosis Gene Mutations? , 2018, The American journal of surgical pathology.
[17] F. Algaba,et al. Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[18] P. Argani,et al. Re‐evaluation of 33 ‘unclassified’ eosinophilic renal cell carcinomas in young patients , 2018, Histopathology.
[19] S. Hammes,et al. Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target , 2017, Steroids.
[20] D. Berney,et al. Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC): Further Morphologic and Molecular Characterization of ESC RCC as a Distinct Entity , 2017, The American journal of surgical pathology.
[21] R. Varadhan,et al. Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation , 2016, Leukemia.
[22] C. Porta,et al. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma , 2016, Clinical Cancer Research.
[23] A. Sangoi,et al. Eosinophilic, Solid, and Cystic Renal Cell Carcinoma: Clinicopathologic Study of 16 Unique, Sporadic Neoplasms Occurring in Women , 2016, The American journal of surgical pathology.
[24] D. Grignon,et al. Renal cell carcinoma with angioleiomyoma-like stroma: clinicopathological, immunohistochemical, and molecular features supporting classification as a distinct entity , 2015, Modern Pathology.
[25] P. Argani,et al. t(6;11) Renal Cell Carcinoma (RCC): Expanded Immunohistochemical Profile Emphasizing Novel RCC Markers and Report of 10 New Genetically Confirmed Cases , 2014, The American journal of surgical pathology.
[26] E. Montgomery,et al. A broad survey of cathepsin K immunoreactivity in human neoplasms. , 2013, American journal of clinical pathology.
[27] A. Ziober,et al. The Use of Immunohistochemical Expression of SF-1 and EMA in Distinguishing Adrenocortical Tumors From Renal Neoplasms , 2012, Applied immunohistochemistry & molecular morphology : AIMM.
[28] M. Ladanyi,et al. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions , 2011, Modern Pathology.
[29] A. Gown,et al. Pure Epithelioid PEComas (So-Called Epithelioid Angiomyolipoma) of the Kidney: A Clinicopathologic Study of 41 Cases: Detailed Assessment of Morphology and Risk Stratification , 2011, The American journal of surgical pathology.
[30] M. Ladanyi,et al. PRCC-TFE3 Renal Carcinomas: Morphologic, Immunohistochemical, Ultrastructural, and Molecular Analysis of an Entity Associated With the t(X;1)(p11.2;q21) , 2002, The American journal of surgical pathology.
[31] J. Blenis,et al. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. , 2002, Genes & development.
[32] M. Ladanyi,et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. , 2001, The American journal of pathology.
[33] M. Miettinen,et al. Keratin subsets in spindle cell sarcomas. Keratins are widespread but synovial sarcoma contains a distinctive keratin polypeptide pattern and desmoplakins. , 1991, The American journal of pathology.